Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$5.95 - $15.79 $14,047 - $37,280
2,361 Added 18.59%
15,059 $237,000
Q2 2023

Apr 29, 2024

BUY
$4.89 - $10.57 $62,093 - $134,217
12,698 New
12,698 $126,000
Q1 2023

May 09, 2024

BUY
$5.62 - $11.51 $71,362 - $146,153
12,698 New
12,698 $73.6 Million
Q4 2022

May 10, 2024

SELL
$2.32 - $10.97 $6,096 - $28,829
-2,628 Reduced 17.15%
12,698 $100,000
Q4 2022

Mar 22, 2023

SELL
$2.32 - $10.97 $6,096 - $28,829
-2,628 Reduced 17.15%
12,698 $100,000
Q4 2022

Feb 15, 2023

BUY
$2.32 - $10.97 $29,459 - $139,297
12,698 New
12,698 $100,000
Q2 2022

Aug 11, 2022

SELL
$5.7 - $10.33 $87,358 - $158,317
-15,326 Closed
0 $0
Q1 2022

May 10, 2024

BUY
$4.41 - $22.5 $67,587 - $344,835
15,326 New
15,326 $107,000
Q1 2022

Jun 20, 2023

BUY
$4.41 - $22.5 $11,589 - $59,130
2,628 Added 20.7%
15,326 $107,000
Q1 2022

Mar 22, 2023

BUY
$4.41 - $22.5 $44,404 - $226,552
10,069 Added 191.54%
15,326 $107,000
Q1 2022

May 12, 2022

BUY
$4.41 - $22.5 $44,404 - $226,552
10,069 Added 191.54%
15,326 $108,000
Q4 2021

Jun 21, 2023

SELL
$21.07 - $34.98 $156,781 - $260,286
-7,441 Reduced 58.6%
5,257 $120,000
Q3 2021

May 17, 2024

BUY
$24.85 - $40.25 $130,636 - $211,594
5,257 New
5,257 $155,000
Q3 2021

Jun 21, 2023

SELL
$24.85 - $40.25 $184,908 - $299,500
-7,441 Reduced 58.6%
5,257 $155,000
Q3 2021

Mar 22, 2023

SELL
$24.85 - $40.25 $184,908 - $299,500
-7,441 Reduced 58.6%
5,257 $155,000
Q3 2021

Nov 15, 2021

BUY
$24.85 - $40.25 $130,636 - $211,594
5,257 New
5,257 $156,000

Others Institutions Holding ICVX

About Icosavax, Inc.


  • Ticker ICVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,885,200
  • Description
  • Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical tri...
More about ICVX
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.